文献速递其他结缔组织病

重新思考美国结缔组织病相关雷诺现象疼痛的药物治疗策略

Rethinking Strategies for a Pharmaceutical Approach to Pain Related to Connective Tissue-Related Raynaud Phenomenon in the United States.
PubMed 文献 · Arthritis Care Res (Hoboken) · 2025-12-12

美国尚无获批的雷诺现象(RP)治疗药物,临床试验受设计挑战。该叙述性综述通过系统检索截至2025年9月1日的RP治疗指南,发现共纳入4篇指南或推荐,指南-based照护未纳入RP疼痛管理。RP疼痛结局测量已有进展,大型美国系统性硬化症登记库可提供真实世界药物镇痛疗效数据。

要点

  • 美国无获批RP治疗药物,指南-based照护未纳入RP疼痛管理。
  • RP疼痛结局测量与机制定量已有进展,可用于临床试验。
  • 大型美国系统性硬化症登记库可收集RP及指端病变真实世界数据。

核心结论

  • RP疼痛管理未纳入指南-based照护,美国尚无获批RP治疗药物。
  • RP疼痛结局测量已有进展,大型美国登记库可提供药物镇痛疗效的真实世界数据。

研究设计与样本

  • 叙述性综述,通过综合检索策略检索截至2025年9月1日发表的RP治疗指南。
  • 检索数据库包括Medline(PubMed)、Embase和Scopus,索引词为「Raynaud's phenomenon treatment guidelines」。
  • 若学会指南更新,仅纳入最新版;资格、数据提取、偏倚风险和质量评估由两名独立审阅者审核,分歧由第三名审阅者解决。

主要发现

  • 检索词「Raynaud's phenomenon treatment guidelines」共识别118篇已发表文章,审阅27篇摘要。
  • 4篇作为RP治疗推荐或指南的文章进行了全文审阅。
  • RP疼痛管理未纳入指南-based照护。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: There are no US Food and Drug Administration-approved therapies for Raynaud phenomenon (RP) in the United States. Clinical trials have been challenged by study design. Important advances in RP patient-reported outcome measures and mechanistic quantification allow RP-related pain characterization. The rationale for this narrative review is current RP treatment guidelines that focus on vasodilation. METHODS: The question of why there are limitations to RP treatment in the United States is addressed through a comprehensive search strategy of published RP treatment guidelines up until September 1, 2025. Search databases included Medline (PubMed), Embase, and Scopus for the index terms "Raynaud's phenomenon treatment guidelines." If a society guideline was updated, only the most recent was included. Eligibility, data extraction, risk of bias, and quality assessment were subject to review by two independent reviewers, with a third reviewer resolving discrepancies. US-specific considerations of published guidelines are reviewed. RESULTS: A total of 118 published articles were identified by the search terms "Raynaud's phenomenon treatment guidelines," and 27 abstracts were reviewed. Four articles published as RP treatment recommendations or guidelines were reviewed for full content. Pain management for RP is not included in guideline-based care. CONCLUSION: There are advances in outcome measures for quantifying pain now available for RP clinical trials. Large US-based registries for systemic sclerosis using patient-reported outcomes can allow serial data collection on RP and RP-related digital lesions to provide real-world data on medication efficacy for pain relief.

来源:Arthritis Care Res (Hoboken),查看原文。版权归原作者所有。

引用

  1. Frech TM, Frech CG, Merryman WD, et al. Rethinking Strategies for a Pharmaceutical Approach to Pain Related to Connective Tissue-Related Raynaud Phenomenon in the United States. Arthritis Care Res (Hoboken). 2025. PMID: 40999744. doi:10.1002/acr.25660

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。